Press

The 'AseBio Journalism Awards', organized within the framework of BIOSPAIN 2023, recognize the work of journalists Belén Diego and Miguel Sanmartín

22/02/2024

BioSpain · Communication

• Belén Diego is a contributor to Diariofarma and correspondent for APM Health Europe in Spain and Portugal, while Miguel Sanmartín is the founder of Capital Radio and host of the program 'Biotecnología Capital'.
• The winning pieces have been chosen as the two best coverages of BIOSPAIN 2023 by the jury among all the received nominations.
• Following the award ceremony, a debate with professionals in scientific communication has been held, where the main challenges and opportunities were analyzed.

AseBio

Biotechnology, key in reducing dependence on fossil fuels and developing alternative energy sources

14/02/2024

Climate change · Bioeconomy · Circular economy

• Coal, oil, and gas account for over 75% of total global greenhouse gas emissions and nearly 90% of all carbon dioxide emissions.
• Biotechnology is crucial in reducing the use of fossil fuels and in the development of alternative energy sources that are clean, accessible, affordable, sustainable, and reliable.
• Bioenergy, biofuels, biological treatment of waste and wastewater, reduction of atmospheric emissions, or improvement of energy efficiency are just some examples of the responses offered by the biotechnology sector to this challenge.

AseBio

AseBio positively values the regulatory advancements regarding NGTs following the European Parliament's vote

08/02/2024

Agrifood · Food & feed · Agriculture

• Europe aims to progress towards a more sustainable and resilient food system through the development of improved plant varieties.
• Following the vote on February 7th, the European Parliament will be able to initiate negotiations with the Member States for the creation of the definitive law.
• We hope that the approval of this law will occur before the European elections taking place between June 6th and 9th, 2024.

AseBio

AseBio, AEPLA, ANOVE, and the ANTAMA Foundation urge European legislators to vote in favor of the proposed adequate regulation on NGTs

06/02/2024

Agrifood · Food & feed · Agriculture

• The Parliament is expected to adopt its mandate during the plenary session on February 7, 2024, after which it will be ready to commence negotiations with EU Member States.
• It is crucial not to miss the opportunity to progress in the approval of this regulation, as it will contribute to establishing more appropriate and aligned regulations regarding plants and products resulting from NGTs.
• The European Union has the opportunity to promote a safer, more sustainable, and more resilient agri-food system, but it is necessary to establish an adequate, predictable regulatory framework that enhances innovations derived from these techniques.

AseBio

Biotechnology is revolutionizing the present and future of the fight against cancer

02/02/2024

Healthcare · Access to innovation · Drug discovery · Innovative drugs · Personalized medicine · Advanced therapies

• Immunotherapy, gene therapy, the study of mRNA and its potential application in vaccines, nanotechnology, liquid biopsy, the development of specific biomarkers, and CAR-T cells are just a few examples of biotechnological advances against cancer.
• Sixty-three percent of AseBio's pipeline research (350 research lines from national and multinational companies with subsidiaries in Spain) is focused on finding a treatment for cancer.
• Furthermore, 28% of disease diagnostic products developed by our partner companies are targeted towards cancer.

AseBio

AseBio values positively the vote on NGTs, but the proposal to ban patents could hinder innovation in the European Union

26/01/2024

Agrifood · Food & feed · Agriculture

• Members of the European Parliament have agreed with the proposal to have two different categories and two sets of rules for plants derived from the use of NGTs.
• The total ban on patents for all plants obtained through the use of NGTs, claiming to avoid "legal uncertainties, higher costs, and new dependencies for farmers and breeders," will discourage agricultural innovation and genetic editing techniques in Europe.
• The Parliament is expected to adopt its mandate during the plenary session from February 5 to 8, 2024, after which it will be ready to start negotiations with EU member states.

AseBio

AseBio and Alira Health announce Market Access Mentoring Program for 2024

25/01/2024

Corporate

• The 2024 program application will open on January 25th and close on February 21st.
• The 2024 edition format includes a 40-hour service package for three companies that includes an initial meeting, background analysis, tailored orientation session for market access and pricing, and gap analysis.

AseBio

The European Union Pharmaceutical Legislation proposal jeopardizes biotechnological innovation

24/01/2024

Healthcare · Access to innovation · Financing

• This is evident in the study conducted by EuropaBio, titled "Impact of the General Pharmaceutical Legislation of the European Union on the Innovation Ecosystem and Biotechnological Companies in Europe."
• The study highlights that the European Commission's proposal sends a concerning message to investors and innovative companies: the European Union has sidelined innovation in the field of health.
• The only way for the European Union to meet the current needs of patients, the economy, and its long-term resilience is to prioritize high levels of innovation in biotechnology.

AseBio

The third edition of the AseBio Forum – TERAV – Ciber on advanced therapies analyzes the challenges of academic research and the industrial capabilities of the biotechnological sector in Spain

19/01/2024

Healthcare · Advanced therapies

• The technical meeting and collaborative forum have been held under the title "Applications of non-viral vectors in gene editing and therapy: Challenges for academia and industry."
• More than 30 biotechnological companies in our country have the capabilities for the complete development of advanced therapies, from the initial R&D phases to more advanced processes such as manufacturing, transfer, and distribution.
• The commitment to advanced therapies will not only address diseases but also increase Europe's competitiveness and ensure affordable access to innovative medicines.

AseBio